Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 2/20 | 0.41 |
| ▸ | RAB9A | P51151 | 2/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.41 |
| ▸ | DCTPP1 | Q9H773 | 1/20 | 0.40 |
| ▸ | ELANE | P08246 | 4/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.40 |
| ▸ | OPRL1 | P41146 | 2/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | GNRHR | P30968 | 1/20 | 0.37 |
| ▸ | TP53 | P04637 | 1/20 | 0.37 |
| ▸ | HPGD | P15428 | 1/20 | 0.37 |
| ▸ | BRD4 | O60885 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1806228 | 0.87 | ELANE (0.44) | NPC1RAB9AMAPK1NPSR1DCTPP1 | |
| SCHEMBL1806069 | 0.85 | NPC1 (0.42) | NPC1RAB9AMAPK1NPSR1DCTPP1 | |
| SCHEMBL1808293 | 0.82 | NPC1 (0.39) | NPC1RAB9AMAPK1NPSR1DCTPP1 | |
| SCHEMBL1806834 | 0.82 | ELANE (0.44) | NPC1RAB9AMAPK1NPSR1DCTPP1 | |
| SCHEMBL1806594 | 0.81 | DCTPP1 (0.45) | NPC1RAB9AMAPK1NPSR1DCTPP1 | |
| SCHEMBL1806316 | 0.81 | NPC1 (0.44) | NPC1RAB9AMAPK1NPSR1DCTPP1 | |
| SCHEMBL1805340 | 0.80 | NPC1 (0.43) | NPC1RAB9AMAPK1NPSR1DCTPP1 | |
| SCHEMBL11971975 | 0.79 | GNRHR (0.41) | MAPK1NPSR1OPRL1GNRHR | |
| SCHEMBL1805919 | 0.78 | ELANE (0.47) | NPC1RAB9AMAPK1NPSR1DCTPP1 | |
| SCHEMBL1806339 | 0.77 | OPRL1 (0.46) | NPC1RAB9AOPRL1HTTKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2501703-B1 | SPIROPIPERIDINE COMPOUNDS AS ORL-1 RECEPTOR ANTAGONISTS | LILLY CO ELI (US) | 2013-09-18 | — | — | EP | disclosed |
| EP-2501703-A1 | SPIROPIPERIDINE COMPOUNDS AS ORL-1 RECEPTOR ANTAGONISTS | Eli Lilly and Company (US) | 2012-09-26 | — | — | EP | disclosed |
| US-8232289-B2 | Spiropiperidine compounds as ORL-1 receptor antagonists | ELI LILLY AND COMPANY (US) | 2012-07-31 | — | — | US | disclosed |
| WO-2011060035-A1 | SPIROPIPERIDINE COMPOUNDS AS ORL-1 RECEPTOR ANTAGONISTS | ELI LILLY AND COMPANY (US) | 2011-05-19 | — | — | WO | disclosed |
| US-20110118251-A1 | SPIROPIPERIDINE COMPOUNDS AS ORL-1 RECEPTOR ANTAGONISTS | ELI LILLY AND COMPANY (US) | 2011-05-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110118251-A1 | SPIROPIPERIDINE COMPOUNDS AS ORL-1 RECEPTOR ANTAGONISTS | OXER1, OGFRL1, ORMDL3 | NPC1 1377/4885RAB9A 3218/4885MAPK1 909/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.